Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Cyclacel Pharmaceuticals, Inc. - 6% Convertible Preferred Stock (NQ: CYCCP )

6.470 UNCHANGED
Streaming Delayed Price Updated: 2:09 PM EST, Dec 23, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Cyclacel Pharmaceuticals, Inc. - 6% Convertible Preferred Stock

< Previous 1 2 Next >
Cyclacel Pharmaceuticals Announces Its Exploration of Potential Strategic Alternatives and Reduction of Operating Costs
From Cyclacel
Via GlobeNewswire
Cyclacel Pharmaceuticals Announces Closing of Exercise of Warrants for $2.1 Million Gross Proceeds
From Cyclacel
Via GlobeNewswire
Cyclacel Pharmaceuticals Announces Exercise of Warrants for $2.1 Million Gross Proceeds
From Cyclacel
Via GlobeNewswire
Cyclacel Pharmaceuticals Reports Third Quarter Financial Results and Provides Business Update
From Cyclacel
Via GlobeNewswire
Cyclacel Pharmaceuticals Announces That Nasdaq Granted an Extension to Regain Compliance With the Equity Standard Rule
From Cyclacel
Via GlobeNewswire
Cyclacel Pharmaceuticals Reports New Clinical Data from Ongoing, Phase 2 Study of Oral Fadraciclib at the 2024 EORTC-NCI-AACR Symposium
- Interim data for fadraciclib monotherapy in patients with advanced solid tumors preselected for CDKN2A and/or CDKN2B abnormalities - 
From Cyclacel
Via GlobeNewswire
Cyclacel Pharmaceuticals to Present New Clinical Data From Phase 2 Study of Oral Fadraciclib at the 2024 EORTC-NCI-AACR Symposium
Initial safety and efficacy data from fadraciclib monotherapy in patients with advanced solid tumors preselected for CDKN2A and/or CDKN2B abnormalities 
From Cyclacel
Via GlobeNewswire
Cyclacel Pharmaceuticals Announces Completion of Enrollment in the Biomarker-Enriched Patient Cohort of Its Phase 2 Study
From Cyclacel
Via GlobeNewswire
Cyclacel Pharmaceuticals Announces Participation at the H.C. Wainwright 26th Annual Global Investment Conference
From Cyclacel
Via GlobeNewswire
Cyclacel Pharmaceuticals Confirms It Has Filed an Appeal to Nasdaq Staff Delisting Letter
Delisting or suspension action stayed pending the issuance of a final decision 
From Cyclacel
Via GlobeNewswire
Cyclacel Pharmaceuticals Reports Second Quarter Financial Results and Provides Business Update
From Cyclacel
Via GlobeNewswire
Cyclacel Pharmaceuticals to Release Second Quarter 2024 Financial Results
From Cyclacel
Via GlobeNewswire
Cyclacel Announces Notice of Intention to Grant New European Patent Covering Plogosertib Pharmaceutical Compositions
Lengthens Patent Exclusivity of Plogosertib until August 2040 
From Cyclacel
Via GlobeNewswire
Cyclacel’s Fadraciclib Demonstrates Efficacy in Patient-Derived Colorectal Cancer Models at the 2024 ASCO Annual Meeting
From Cyclacel
Via GlobeNewswire
Cyclacel Pharmaceuticals Reports New Clinical Data at 2024 ASCO Annual Meeting Highlighting Oral Fadraciclib’s Potential as a Precision Medicine for Cancer
From Cyclacel
Via GlobeNewswire
Cyclacel Pharmaceuticals Reports First Quarter Financial Results and Provides Business Update
From Cyclacel
Via GlobeNewswire
Cyclacel Pharmaceuticals to Release First Quarter 2024 Financial Results
From Cyclacel
Via GlobeNewswire
Cyclacel Pharmaceuticals Announces Closing of $8.0 Million Private Placement Priced At-The-Market Under NASDAQ Rules
From Cyclacel
Via GlobeNewswire
Cyclacel Pharmaceuticals Announces $8.0 Million Private Placement Priced At-The-Market Under Nasdaq Rules
From Cyclacel
Via GlobeNewswire
Cyclacel Pharmaceuticals to Present New Clinical Data at 2024 ASCO Annual Meeting Highlighting Fadraciclib’s Potential as a Precision Medicine for Cancer
From Cyclacel
Via GlobeNewswire
Cyclacel Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
From Cyclacel
Via GlobeNewswire
Cyclacel Pharmaceuticals to Release Fourth Quarter and Full Year 2023 Financial Results
From Cyclacel
Via GlobeNewswire
Cyclacel Pharmaceuticals Announces Preclinical Proof-of-Concept Data for Fadraciclib to be Presented at the American Association for Cancer Research (AACR) Annual Meeting 2024
Data support ongoing development program of novel CDK2/9 inhibitor fadraciclib in patients with solid tumors and lymphoma 
From Cyclacel
Via GlobeNewswire
Cyclacel Pharmaceuticals Announces Receipt of $2.9 Million R&D Tax Credit
From Cyclacel
Via GlobeNewswire
Cyclacel Pharmaceuticals to Participate in 2024 BIO CEO & Investor Conference
From Cyclacel
Via GlobeNewswire
Cyclacel Pharmaceuticals Announces the Appointment of Brian Schwartz, M.D. as Chief Medical Officer
From Cyclacel
Via GlobeNewswire
Cyclacel Pharmaceuticals Regains Compliance With Nasdaq Minimum Bid Price Requirement
From Cyclacel
Via GlobeNewswire
Cyclacel Pharmaceuticals to Present at Biotech Showcase 2024
From Cyclacel
Via GlobeNewswire
Cyclacel Pharmaceuticals Announces Registered Direct and Private Placement Offering Priced At-The-Market Under Nasdaq Rules
From Cyclacel
Via GlobeNewswire
Cyclacel Pharmaceuticals Reports Fadraciclib Phase 1 Data Suggesting Efficacy Against Tumors With CDKN2A, CDKN2B and MTAP Deletions
From Cyclacel
Via GlobeNewswire
< Previous 1 2 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.